Belite Bio Chief Scientific Officer Nathan L. Mata Sells 1,000 ADS Shares Under Rule 10b5-1 Plan

Nathan L. Mata, Chief Scientific Officer of Belite Bio, Inc. (NASDAQ: BLTE), sold 1,000 American depositary shares (ADS) on April 17, 2026, through six separate transactions executed under a Rule 10b5-1 trading plan adopted on December 10, 2025. The sales occurred at weighted average prices ranging from $158.4563 to $163.3250 per share, with individual transactions ranging from 32 to 274 shares. Following these sales, Mata's direct holdings in the company decreased from 14,666 ADS to 13,666 ADS. Each ADS represents one ordinary share of the company. The transactions were pre-scheduled under the Rule 10b5-1 plan, which allows company insiders to establish predetermined trading arrangements to avoid potential allegations of trading on material non-public information.